96 related articles for article (PubMed ID: 12162880)
1. Proteolytic balance in patients with multiple sclerosis during interferon treatment.
Giannelli G; De Marzo A; Scagnolari C; Bergamini C; Fransvea E; Bagnato F; Bellomi F; Millefiorini E; Gasperini C; Antonaci S; Antonelli G
J Interferon Cytokine Res; 2002 Jun; 22(6):689-92. PubMed ID: 12162880
[TBL] [Abstract][Full Text] [Related]
2. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.
Gilli F; Bertolotto A; Sala A; Hoffmann F; Capobianco M; Malucchi S; Glass T; Kappos L; Lindberg RL; Leppert D
Brain; 2004 Feb; 127(Pt 2):259-68. PubMed ID: 14607790
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
Boz C; Ozmenoglu M; Velioglu S; Kilinc K; Orem A; Alioglu Z; Altunayoglu V
Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
[TBL] [Abstract][Full Text] [Related]
4. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment.
Avolio C; Filippi M; Tortorella C; Rocca MA; Ruggieri M; Agosta F; Tomassini V; Pozzilli C; Stecchi S; Giaquinto P; Livrea P; Trojano M
Mult Scler; 2005 Aug; 11(4):441-6. PubMed ID: 16042227
[TBL] [Abstract][Full Text] [Related]
5. IFN-beta1a may increase serum levels of TIMP-1 in patients with relapsing-remitting multiple sclerosis.
Waubant E; Gee L; Miller K; Stabler G; Goodkin D
J Interferon Cytokine Res; 2001 Mar; 21(3):181-5. PubMed ID: 11331041
[TBL] [Abstract][Full Text] [Related]
6. Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis.
Comabella M; Río J; Espejo C; Ruiz de Villa M; Al-Zayat H; Nos C; Deisenhammer F; Baranzini SE; Nonell L; López C; Julià E; Oksenberg JR; Montalban X
Clin Immunol; 2009 Feb; 130(2):145-50. PubMed ID: 18945642
[TBL] [Abstract][Full Text] [Related]
7. Effect of interferon beta-1a on serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis patients. One year follow-up results.
Karabudak R; Kurne A; Guc D; Sengelen M; Canpinar H; Kansu E
J Neurol; 2004 Mar; 251(3):279-83. PubMed ID: 15015006
[TBL] [Abstract][Full Text] [Related]
8. Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.
Alexander JS; Harris MK; Wells SR; Mills G; Chalamidas K; Ganta VC; McGee J; Jennings MH; Gonzalez-Toledo E; Minagar A
Mult Scler; 2010 Jul; 16(7):801-9. PubMed ID: 20621951
[TBL] [Abstract][Full Text] [Related]
9. Increased expression ratio of matrix metalloproteinase-9 (MMP9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) RNA levels in Iranian multiple sclerosis patients.
Nazdik MK; Taheri M; Sajjadi E; Arsang-Jang S; Koohpar ZK; Inoko H; Sayad A
Hum Antibodies; 2016; 24(3-4):65-70. PubMed ID: 27689613
[TBL] [Abstract][Full Text] [Related]
10. IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS.
Waubant E; Goodkin D; Bostrom A; Bacchetti P; Hietpas J; Lindberg R; Leppert D
Neurology; 2003 Jan; 60(1):52-7. PubMed ID: 12525717
[TBL] [Abstract][Full Text] [Related]
11. Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients.
Bernal F; Elias B; Hartung HP; Kieseier BC
Mult Scler; 2009 Jun; 15(6):721-7. PubMed ID: 19383643
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis.
Benesová Y; Vasku A; Novotná H; Litzman J; Stourac P; Beránek M; Kadanka Z; Bednarík J
Mult Scler; 2009 Mar; 15(3):316-22. PubMed ID: 19153173
[TBL] [Abstract][Full Text] [Related]
13. Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis.
Yushchenko M; Mäder M; Elitok E; Bitsch A; Dressel A; Tumani H; Bogumil T; Kitze B; Poser S; Weber F
J Neurol; 2003 Oct; 250(10):1224-8. PubMed ID: 14586607
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinase-7 and matrix metalloproteinase-9 in pediatric multiple sclerosis.
Yılmaz Ü; Gücüyener K; Atak A; Aral A; Gürkaş E; Demir E; Serdaroğlu A
Pediatr Neurol; 2012 Sep; 47(3):171-6. PubMed ID: 22883281
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients.
Galboiz Y; Shapiro S; Lahat N; Rawashdeh H; Miller A
Ann Neurol; 2001 Oct; 50(4):443-51. PubMed ID: 11601495
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis.
Fainardi E; Castellazzi M; Bellini T; Manfrinato MC; Baldi E; Casetta I; Paolino E; Granieri E; Dallocchio F
Mult Scler; 2006 Jun; 12(3):294-301. PubMed ID: 16764342
[TBL] [Abstract][Full Text] [Related]
18. TIMP-1 resistant matrix metalloproteinase-9 is the predominant serum active isoform associated with MRI activity in patients with multiple sclerosis.
Trentini A; Manfrinato MC; Castellazzi M; Tamborino C; Roversi G; Volta CA; Baldi E; Tola MR; Granieri E; Dallocchio F; Bellini T; Fainardi E;
Mult Scler; 2015 Aug; 21(9):1121-30. PubMed ID: 25662349
[TBL] [Abstract][Full Text] [Related]
19. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes.
Avolio C; Ruggieri M; Giuliani F; Liuzzi GM; Leante R; Riccio P; Livrea P; Trojano M
J Neuroimmunol; 2003 Mar; 136(1-2):46-53. PubMed ID: 12620642
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing antibodies, MxA expression and MMP-9/TIMP-1 ratio as markers of bioavailability of interferon-beta treatment in multiple sclerosis patients: a two-year follow-up study.
Garcia-Montojo M; Dominguez-Mozo MI; de las Heras V; Bartolome M; Garcia-Martinez A; Arroyo R; Alvarez-Lafuente R
Eur J Neurol; 2010 Mar; 17(3):470-8. PubMed ID: 20050906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
